Quantitative electroencephalography

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024
Research, Corporation, Conference, DLB, Alzheimer's disease, Disease, Biomarker, Public expenditure, Translational Neurodegeneration, Completeness, Vance DeGeneres, Protein, Clinical trial, Quantitative electroencephalography, Therapy, NIA, SHIMMER, Cognition, Pharmaceutical industry

PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. Management will host a live webcast conference call at 8:00am ET to review 2023 accomplishments. Details of the call are provided below.

Key Points: 
  • ET -
    PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Cognition scientists published two manuscripts and made 11 presentations at medical and scientific congresses in 2023, advancing the understanding of its foundational science and clinical implications.
  • “We achieved a number of critical clinical objectives in 2023,” said Lisa Ricciardi, Cognition’s president and CEO .
  • Management will host a conference call and live webcast to discuss Cognition’s financial results today at 8:00 a.m.

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
Central nervous system, Quarter, EMA, Focal seizure, Research, New Drug Application, UCB, FDA, Partnership, Food, Part, Quantitative electroencephalography, SCN8A, Tremor, SCN2A, Safety, PPR, European Medicines Agency, CNS, EEG, Pharmacokinetics, Part 1, Patient, Essential tremor, Medicine, Epilepsy, DEE, Trial of the century, NDA, Ageing, Central nervous system disease, Seizure, Pharmaceutical industry

Fourth Quarter and Full Year 2023 Financial Results:

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    As of December 31, 2023, Praxis had $81.3 million in cash and cash equivalents, compared to $100.5 million in cash, cash equivalents and marketable securities as of December 31, 2022.
  • Research and development expenses were $18.4 million for the fourth quarter of 2023, compared to $28.3 million for the fourth quarter of 2022.
  • General and administrative expenses were $9.9 million for the fourth quarter of 2023, compared to $13.1 million for the fourth quarter of 2022.
  • Praxis incurred a net loss of $26.9 million for the fourth quarter of 2023, including $5.7 million of stock-based compensation expense, compared to $41.2 million for the fourth quarter of 2022, including $6.4 million of stock-based compensation expense.

Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio

Retrieved on: 
Monday, January 8, 2024
Therapeutic index, Essential tremor, Partnership, EEG, SCN2A, Epilepsy, Quantitative electroencephalography, American Epilepsy Society, PPR, NDA, Praxis, New Drug Application, Study, CNS, Part, Poster, Central nervous system, Patient, Seizure, Intellectual disability, Pharmaceutical industry

BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on its portfolio and planned key milestones in 2024:

Key Points: 
  • Praxis made strong progress in developing PRAX-628 for focal epilepsy, which affects over 1 million Americans.
  • Initial data from PRAX-628 show it has a good tolerability profile, a potentially wide therapeutic index and reaching efficacious concentrations within 24 hours.
  • A preliminary analysis of the 15 mg cohort showed that this cohort exceeds the expectations in terms of drug activity.
  • In 2023, Praxis disclosed results from a Phase 1 dose escalation study of PRAX-628 in healthy volunteers:
    PRAX-628 was generally well-tolerated at all tested doses.

Gate Neurosciences Announces Positive Topline Human EEG Biomarker Results Demonstrating Dose-Dependent Target Activation in Phase 1 Study of Apimostinel

Retrieved on: 
Tuesday, November 7, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Pharmacology, Trial of the century, Phase II, MDD, Biomarker, IV, CSF, DSM-IV codes, Gate, Zelquistinel, Neuroscience, Medicine, Safety, Quantitative electroencephalography, NMDA, Patient, POC, Pharmaceutical industry, Vaccine, Apimostinel

Gate Neurosciences , a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced positive topline qEEG biomarker and safety results from its Phase 1 multiple ascending dose study of apimostinel in healthy volunteers.

Key Points: 
  • Gate Neurosciences , a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced positive topline qEEG biomarker and safety results from its Phase 1 multiple ascending dose study of apimostinel in healthy volunteers.
  • Results demonstrated a dose-dependent increase in qEEG pharmacodynamic biomarkers of NMDA receptor target activation from baseline, compared with subjects who received placebo.
  • Apimostinel was also generally well-tolerated with no ketamine-like dissociative side effects, highlighting its novel mechanistic approach of enhancing synaptic function.
  • Gate plans to initiate a Phase 2 study of zelquistinel to confirm efficacy in MDD in Q1 2024.

Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD

Retrieved on: 
Tuesday, October 24, 2023
Optimism, Jort, AECC, Dementia, Clinical trial, Poster, Brain, EEG, Synaptic, Cognition, Therapy, Amsterdam, Quantitative electroencephalography, SEQUEL, Communication, Medical device, Medical imaging

SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D., Ph.D., acting as principal investigator.

Key Points: 
  • SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D., Ph.D., acting as principal investigator.
  • The poster describing changes in brain wave patterns in adults with mild-to-moderate Alzheimer’s disease following 28-days of treatment with CT1812 or placebo will be on display through the conclusion of CTAD.
  • In the SEQUEL study , CT1812-treated participants exhibited a statistically significant change in relative theta in the central region of the brain and consistent trends of improvement across all prespecified EEG parameters.
  • “CT1812 treatment showed improvement of EEG parameters that are consistent in magnitude and effect size with previously reported trials,” explained Dr. de Haan.

NeuroTherapia Presents Clinical Data from Phase 1b Clinical Trial of NTRX-07 for the Treatment of Alzheimer’s Disease

Retrieved on: 
Tuesday, October 24, 2023
Plasma, AD, Biotechnology, CNS, Clinical trial, ADAS-Cog, Neuroinflammation, EEG, Quantitative electroencephalography, Patient, Central nervous system, Pharmaceutical industry

CLEVELAND, Oct. 24, 2023 (GLOBE NEWSWIRE) -- NeuroTherapia, Inc., a clinical-stage, privately held biotechnology company developing oral, small molecule drugs to address neuroinflammatory conditions of the central nervous system (CNS), today announced the presentation of clinical data from its Phase 1b clinical trial of NTRX-07, an oral, small molecule CB2-targeting therapy in development for the treatment of Alzheimer’s disease (AD), in healthy volunteers and a subset of patients with mild cognitive impairment or early AD, at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place in Boston, Mass., Oct. 24-27, 2023.

Key Points: 
  • The early signs of clinical activity we observed in the AD patients included in the study were even more encouraging.
  • 32 participants, including one cohort of 8 patients with early-stage AD, received NTRX-07 or a placebo for seven days in a double-blind, randomized clinical study.
  • The safety profile of NTRX-07 supports further clinical development, with no dose-limiting or serious adverse events observed during the trial.
  • "This data gives us additional confidence that NTRX-07 could become a valuable treatment option and based on its safety profile, could be used in combination with approved antibody treatments.”

Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Tuesday, August 8, 2023
Retina, Vance DeGeneres, Central nervous system, SHIMMER, Quantitative electroencephalography, SPARC, AMD, CMC, NIA, Geographic atrophy, Cognition, DLB, Cell, ID, Public expenditure, Dementia, Baozou Big News Events, Lilly, Canadian International Council, Donanemab, Synapse, Lewy body, CFO, Webcast, Research, Therapy, Death, BLA, News, SEQUEL, SHINE, Pharmaceutical industry, Eisai

PURCHASE, N.Y., Aug. 08, 2023 (GLOBE NEWSWIRE) --  Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2023 and provided recent business updates.

Key Points: 
  • PURCHASE, N.Y., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2023 and provided recent business updates.
  • We anticipate full study results to be available in the fourth quarter of 2023.
  • Research and development expenses were $8.5 million for the second quarter ended June 30, 2023, compared to $9.1 million for the same period in 2022.
  • ET, to discuss the second quarter corporate and financial update.

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Retrieved on: 
Tuesday, August 8, 2023
Anticonvulsant, GABA, Prolactin, AED, CSE, Psychosis, Quantitative electroencephalography, Food and Drug Administration, Pharmacokinetics, Neuroscience, Doctor of Philosophy, DSM-IV codes, Plasma, EEG, Master of Science, FDA, Epilepsy, Addiction, Food, Safety, Pharmaceutical industry, Dietary supplement

-- Company to host webcast to discuss findings of the Phase 1 study today, August 8, 2023, at 4:30pm ET

Key Points: 
  • Central target engagement, as the treatment group was easily identified in blinded data using qEEG power signature.
  • “The positive topline findings from our recently completed Phase 1 study of BMB-101, together with the observations from the qEEG portion of the study, validate our approach, as we continue to evaluate this important product candidate.
  • The Phase 1 study was conducted in Adelaide, Australia, by CMAX Clinical Research, a clinical trial center specializing in a range of early-phase trials and first-in-human studies.
  • The study evaluated the safety, tolerability, pharmacokinetic (PK), and food effect of BMB-101 in healthy volunteers.

Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study

Retrieved on: 
Monday, August 7, 2023
Tmax, Central nervous system, Quantitative electroencephalography, PPR, SAD, Brain, CNS, Patient, EEG, Generalized tonic–clonic seizure, MAD, Sodium, Pharmaceutical industry, Praxis

BOSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the results from an analysis of EEG activity for subjects in the recent Phase 1 study that demonstrated pharmacodynamic activity across all dose levels for study subjects who received PRAX-628 at first administration as compared with subjects who received placebo.

Key Points: 
  • We look forward to sharing the results of our ongoing Phase 2 PPR study later this year, and soon after initiating a Phase 2 study in focal epilepsy,” said Marcio Souza, president and chief executive officer of Praxis.
  • Summary of PRAX-628 Phase 1 qEEG Analysis:
    In the Phase 1 study, PRAX-628 was administered to 40 healthy participants (PRAX-628 n=30, placebo n=10).
  • Additional results from the PRAX-628 Phase 1 study will be presented at an upcoming medical conference.
  • Based on these studies and the preclinical results, Praxis intends to advance PRAX-628 into a Phase 2 study in focal epilepsy in the first half of 2024.

Viage Therapeutics announces data from a Phase 1 study with DGX-001, a first-in-class oral neurotherapeutic targeting cognitive impairment in patients with Alzheimer's Disease and Parkinson's Disease

Retrieved on: 
Wednesday, July 26, 2023
PD, Quantitative electroencephalography, Vagus nerve, VIAG, Deficit spending, Patient, DSM-IV codes, SAN, Parkinson's disease, Observation, MAD, Mall of America, Neuro, Alzheimer's disease, FDA, Therapy, AD, Psychiatry, Neurology, B cell, AVPR1A, Safety, Pharmaceutical industry

SAN FRANCISCO, July 26, 2023 /PRNewswire/ -- Viage Therapeutics (Viage), a neuroscience company based on a platform of novel neurotherapeutics, today announced positive findings from its Phase 1 study of DGX-001, a first-in class oral therapeutic targeting the AVPR1A receptor in the gut. DGX-001 demonstrated both a favorable safety profile and proof of concept data relating to its mechanism of action (MoA), which modulates the vagus nerve via specific receptor interactions on enteroendocrine cells in the gut, with no systemic exposure of the drug and no need to penetrate the blood brain barrier. The MoA is supported by the observation of brain activity changes, as measured by qEEG, in the subjects dosed with DGX-001. These results support the initiation of a Phase 2 development program targeting mild cognitive impairment in multiple indications including Alzheimer's Disease (AD), and Parkinson's Disease (PD).

Key Points: 
  • The MoA is supported by the observation of brain activity changes, as measured by qEEG, in the subjects dosed with DGX-001.
  • These results support the initiation of a Phase 2 development program targeting mild cognitive impairment in multiple indications including Alzheimer's Disease (AD), and Parkinson's Disease (PD).
  • The key findings from the Phase 1 study demonstrate that DGX-001 has a favorable safety profile and is well-tolerated.
  • Viage Therapeutics, formerly known as Digestome Therapeutics, is backed by investors from the US, China and Japan.